EP0159311B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for inactivating pathogens in blood products
Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1985-02-18
•
Granted: 1989-04-19
•
Expires: 2005-02-18
Abstract
Abstract A method of inactivating viruses in blood products is described, wherein the blood products are heat-treated in a humid or in a solid state in the presence of inorganic or organic hydroxyl group-containing compounds having an H+-dissociation constant of <10-11 in a concentration of more than 0.05 (5% by weight) and less than 0.70 (70% by weight). The hydroxyl group-containing compounds may be water, methanol, ethanol or mannitol. The temperature may amount up to 121 DEG C., the heat treatment may last from 1 s to 100 h. The inactivation method may be applied for producing blood products selected from enzymes, proenzymes including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma, the inactivation destroying any reproducible filterable pathogens that might be present.
Inventors
- 👤 Johann Dr. Eibl
- 👤 Otto Dr. Schwarz
- 👤 Fritz Dr. Elsinger
- 👤 Günter Prof. Dr. Wöber
- 👤 Anton Philapitsch
- 👤 Yendra Dr. Linnau
- 👤 Friedrich Prof. Dr. Dorner
- 👤 Karl Ing. Trambauer
- 👤 Wolfgang Frechinger
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 23:43
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2103/00; A61L2103/05
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
87 words
Method of inactivating reproducible filterable pathogens in blood products under application of an elevated temperature, characterised in that the blood products, in solid state, are adjusted to a content of water, methanol or ethanol of more than 0.05 (5 % by weight) and less than 0.70 (70 % by weight), preferably less than 0.40 (40 % by weight), and are treated in a closed container at a temperature in the range of from 50 to 121°C while increasing the partial vapour pressure of water, methanol or ethanol.
Claim 2
Dependent Claim
87 words
Method of inactivating reproducible filterable pathogens in blood products under application of an elevated temperature, characterised in that the blood products, in solid state, are adjusted to a content of water, methanol or ethanol of more than 0.05 (5 % by weight) and less than 0.70 (70 % by weight), preferably less than 0.40 (40 % by weight), and are treated in a closed container at a temperature in the range of from 50 to 121°C while increasing the partial vapour pressure of water, methanol or ethanol.
Claim 3
Dependent Claim
29 words
Method according to claim 1, characterised in that the treatment of the blood products is carried out with water vapour at a pressure of from 0.1 to 2 bar.
Claim 4
Dependent Claim
27 words
Method according to claims 1 or 2, characterised in that the reproducible filterable pathogens are hepatitis viruses or agents capable of transmitting AIDS (acquired immune deficiency syndrome).
Claim 5
Dependent Claim
26 words
Method according to one of the preceding claims, characterised in that the blood products are treated for a period of from 1 s to 100 h.
Claim 6
Dependent Claim
46 words
Method according to one of the preceding claims, characterised in that the treatment of the blood products is carried out at a water content of from 0.06 (6 % by weight) to 0.30 (30 % by weight) at a temperature of from 50 to 90° C.
Claim 7
Dependent Claim
41 words
Method according to one of the preceding claims, characterised in that the treatment of the blood products is carried out in the presence of an inert protective gas free of oxygen, preferably nitrogen, and optionally in the presence of oxygen-binding substances.
Claim 8
Dependent Claim
25 words
Method according to one of the preceding claims, characterised in that the blood products are treated with water vapour or gaseous methanol and ethanol, respectively.
Claim 9
Dependent Claim
25 words
Method according to one of the preceding claims, characterised in that the blood products are treated in a liquid medium in which they are insoluble.
Claim 10
Dependent Claim
19 words
Method according to claim 8, characterised in that as the liquid medium chloroform or acetic ethyl ester is used.
Claim 11
Dependent Claim
25 words
Method according to one of the preceding claims, characterised in that a blood product is used which is covalently or non-covalently bound to a matrix.
Claim 12
Dependent Claim
25 words
Method according to claim 10, characterised in that a blood product is used which is applied to a tissue-compatible carrier, such as a collagen fleece.
Claim 13
Dependent Claim
25 words
Method according to claim 11, characterised in that a fibrinogen-containing composition is used which is applied to a tissue-compatible carrier, such as a collagen fleece.
Claim 14
Dependent Claim
26 words
Method according to claim 1, characterised in that the inactivated blood products are freed from neoproteins or neoantigens possibly formed during inactivation by further fractionation measures.
Claim 15
Dependent Claim
68 words
Method of producing blood products, selected from the group consisting of enzymes, proenzymes, including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma or mixtures of individual blood products, by applying the method of claims 1 to 13, characterised in that the inactivation is carried out at any desired stage of the production method, whereupon the blood products are, if desired, converted into a galenic preparation.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.